DE602004026903D1 - P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält - Google Patents

P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält

Info

Publication number
DE602004026903D1
DE602004026903D1 DE602004026903T DE602004026903T DE602004026903D1 DE 602004026903 D1 DE602004026903 D1 DE 602004026903D1 DE 602004026903 T DE602004026903 T DE 602004026903T DE 602004026903 T DE602004026903 T DE 602004026903T DE 602004026903 D1 DE602004026903 D1 DE 602004026903D1
Authority
DE
Germany
Prior art keywords
hersesis
glycoprotein inhibitor
anticancer agent
glycoprotein
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004026903T
Other languages
English (en)
Inventor
Keuk Chan Bang
Mi Young Cha
Young Gil Ahn
Young Jin Ham
Maeng Sup Kim
Gwan Sun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of DE602004026903D1 publication Critical patent/DE602004026903D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Structural Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
DE602004026903T 2003-10-07 2004-10-06 P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält Active DE602004026903D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030069582A KR100557093B1 (ko) 2003-10-07 2003-10-07 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PCT/KR2004/002550 WO2005033097A1 (en) 2003-10-07 2004-10-06 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
DE602004026903D1 true DE602004026903D1 (de) 2010-06-10

Family

ID=36500896

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026903T Active DE602004026903D1 (de) 2003-10-07 2004-10-06 P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält

Country Status (23)

Country Link
US (1) US7625926B2 (de)
EP (1) EP1678162B1 (de)
JP (1) JP4481992B2 (de)
KR (1) KR100557093B1 (de)
CN (1) CN1863795B (de)
AT (1) ATE466008T1 (de)
AU (1) AU2004277475B2 (de)
BR (1) BRPI0415053B8 (de)
CA (1) CA2541301C (de)
DE (1) DE602004026903D1 (de)
DK (1) DK1678162T3 (de)
ES (1) ES2342290T3 (de)
HK (1) HK1096399A1 (de)
IL (1) IL174665A (de)
MX (1) MXPA06003803A (de)
NO (1) NO336127B1 (de)
NZ (1) NZ546257A (de)
PL (1) PL1678162T3 (de)
PT (1) PT1678162E (de)
RU (1) RU2317985C1 (de)
SI (1) SI1678162T1 (de)
WO (1) WO2005033097A1 (de)
ZA (1) ZA200603538B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
MX2009009304A (es) * 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
GEP20135849B (en) 2008-09-02 2013-06-10 Novartis Ag Picolinamide derivatives as kinase inhibitors
KR101466245B1 (ko) 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
KR20150013548A (ko) 2012-05-21 2015-02-05 노파르티스 아게 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
KR20150135110A (ko) * 2014-05-23 2015-12-02 한미정밀화학주식회사 p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
EP3893875A1 (de) * 2018-12-14 2021-10-20 Athenex HK Innovative Limited Therapeutische kombinationen aus oral verabreichtem irinotecan und einem p-gp-hemmer zur behandlung von krebs
CA3122766A1 (en) 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer
US20220135548A1 (en) 2019-02-14 2022-05-05 Teva Pharmaceuticals International Gmbh Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5- dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2020230037A1 (en) * 2019-05-13 2020-11-19 Dr. Reddy's Laboratories Limited Alternate process for the preparation of encequidar
WO2021044350A1 (en) * 2019-09-04 2021-03-11 Dr. Reddy’S Laboratories Limited Solid forms of encequidar mesylate and processes thereof
US20230278990A1 (en) 2020-07-10 2023-09-07 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
CA3194694A1 (en) 2020-10-07 2022-04-14 Sameer Urgaonkar Acetamido-phenyltetrazole derivatives and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095213A1 (en) 1990-11-06 1992-05-07 Jotham W. Coe Quinazoline derivatives for enhancing antitumor activity
JP3223193B2 (ja) * 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
ES2103479T3 (es) 1992-07-10 1997-09-16 Glaxo Lab Sa Derivados de anilida.
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
EP1256341A4 (de) * 2000-02-15 2004-12-08 Teijin Ltd Krebs heilmittel das ein anthranilsäurederivat als wirkstoff enthält
KR101060971B1 (ko) 2002-05-14 2011-09-01 제노바 리미티드 안트라닐산 유도체 수화물의 제조 방법
KR100580743B1 (ko) 2003-10-08 2006-05-15 한미약품 주식회사 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법

Also Published As

Publication number Publication date
DK1678162T3 (da) 2010-08-02
AU2004277475A1 (en) 2005-04-14
IL174665A0 (en) 2006-08-20
BRPI0415053B1 (pt) 2019-12-31
NO20062019L (no) 2006-07-06
ATE466008T1 (de) 2010-05-15
CN1863795B (zh) 2011-05-18
HK1096399A1 (en) 2007-06-01
WO2005033097A1 (en) 2005-04-14
JP4481992B2 (ja) 2010-06-16
CA2541301A1 (en) 2005-04-14
RU2317985C1 (ru) 2008-02-27
SI1678162T1 (sl) 2010-07-30
AU2004277475B2 (en) 2007-08-09
KR100557093B1 (ko) 2006-03-03
PT1678162E (pt) 2010-05-19
ZA200603538B (en) 2007-09-26
CA2541301C (en) 2010-02-02
KR20050033734A (ko) 2005-04-13
PL1678162T3 (pl) 2010-09-30
BRPI0415053B8 (pt) 2021-05-25
EP1678162B1 (de) 2010-04-28
JP2007507493A (ja) 2007-03-29
CN1863795A (zh) 2006-11-15
US7625926B2 (en) 2009-12-01
EP1678162A1 (de) 2006-07-12
NZ546257A (en) 2009-09-25
RU2006114427A (ru) 2007-11-20
ES2342290T3 (es) 2010-07-05
NO336127B1 (no) 2015-05-18
BRPI0415053A (pt) 2006-11-28
US20070072900A1 (en) 2007-03-29
IL174665A (en) 2012-10-31
MXPA06003803A (es) 2006-07-03
EP1678162A4 (de) 2008-07-02

Similar Documents

Publication Publication Date Title
DE602004026903D1 (de) P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
SE0400284D0 (sv) Novel compounds
MXPA05009985A (es) Ligandos de receptores de canabinoides.
WO2008016522A3 (en) Hiv reverse transcriptase inhibitors
TW200714583A (en) Substituted gamma lactams as therapeutic agents
ATE297203T1 (de) Antithrombotische mitteln
EP1679309A4 (de) Antistress-arzneimittel und dessen medizinische verwendung
DK1678166T3 (da) Proteinkinaseinhibitorer
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
DE602005016297D1 (de) Antithrombotische diamide
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
EP1714961A4 (de) Indazolverbindung und deren pharmazeutische verwendung
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
WO2008011117A3 (en) Antiviral protease inhibitors
DK1750703T3 (da) Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur
WO2004014868A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
DE60114640D1 (en) Antithrombosemittel
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
GB0212410D0 (en) Organic compounds
ATE382607T1 (de) Antitrombotische aether

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: HANMI HOLDINGS CO., LTD., SEOUL, KR

8364 No opposition during term of opposition
R081 Change of applicant/patentee

Ref document number: 1678162

Country of ref document: EP

Owner name: HANMI SCIENCE CO., LTD., KR

Free format text: FORMER OWNER: HANMI HOLDINGS CO., LTD., SEOUL, KR

Effective date: 20120906

R082 Change of representative

Ref document number: 1678162

Country of ref document: EP

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUS, DE

Effective date: 20120906